How Mukunda was paid
$1.9M in total for Nine months ended December 31, 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Total |
|---|---|---|---|
| Ram MukundaPresident and CEO | $305,000 | $1,530,000 | $1,891,000 |
| Claudia GrimaldiVice President, CCO, and PFO | $177,000 | $510,000 | $706,000 |
What changed and why
- 20%20% increase in both executives’ compensation effective September 2025.
- $1.53M$1.53 million in CEO stock awards included $680 thousand in performance- and market-based awards.
- $17K$17 thousand CEO bonus; bonuses were subject to CALMA completion and successful fundraising milestones.
- $234K$234 thousand in compensation and bonuses payable to Mukunda and $189 thousand to Grimaldi at December 31, 2025.
- $1.891M$1.891 million CEO total compensation for the nine-month transition period, versus $568 thousand in fiscal 2025.
Other IGC Pharma proxy statements
- 2025 proxy statement
Ram Mukunda paid $568,000 (-69% on the year).
Filed Aug 18, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.